RECURRENT SALIVARY GLAND CARCINOMA
Clinical trials for RECURRENT SALIVARY GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SALIVARY GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT SALIVARY GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for rare salivary gland cancer
Disease control OngoingThis study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people whose salivary gland cancer has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. The study includes 45 adults with advanced…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 10:42 UTC
-
Can a blood-flow blocker boost chemo for head and neck cancer?
Disease control OngoingThis study looked at 403 people with head and neck cancer that had come back or spread. It compared standard chemotherapy alone versus chemotherapy plus bevacizumab, a drug that cuts off tumor blood supply. The goal was to see if adding bevacizumab helped people live longer. Resu…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 10:28 UTC
-
Hormone therapy duo takes on rare salivary cancer
Disease control OngoingThis study tests two drugs that lower or block male hormones to treat a rare type of salivary gland cancer that has spread or come back. About 21 people whose cancer has a specific protein (androgen receptor) will take darolutamide pills and get leuprolide shots. The goal is to s…
Matched conditions: RECURRENT SALIVARY GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:01 UTC